Pfizer, Sigma-Tau link up over malaria drug
Pfizer has signed a deal to market Sigma-Tau’s investigational malaria treatment Eurartesim in Africa.
Read MoreAuthor: Kevin Grogan
Destiny gets £4.8 million to develop MRSA drug
Destiny Pharma, the Brighton-based firm which specialises in microbial drugs, has recently secured £4.8 million of extra funding.
Read MoreLilly making job cuts at ImClone; Byetta review delayed
Just a fortnight after completing its $6.5 billion acquisition of ImClone Systems, Eli Lilly is cutting around 30 out of 70 in-house sales rep posts at the US biotechnology firm.
Read MoreNICE setting up consultancy service to advise pharma on trials
The National Institute for Health and Clinical Excellence is following in the footsteps of the US Food and Drug Administration and the European Medicines Agency and setting up a scientific advisory service to guide drugmakers in making their regulatory submissions.
Read MoreBusiness as usual for Phoenix UK as owner Merckle seeks cash
Rumours of the demise of the UK wholesaler Phoenix seem to have been greatly exaggerated says the firm which is part of the huge conglomerate that German billionaire Adolf Merckle is battling to keep afloat.
Read More- FDA approves new high dose Spinraza regimen for SMA
- Viridian reports positive results from elegrobart phase 3 trial
- Cure Parkinson’s convenes expert panel to assess £2 million combination therapy funding call
- Kygevvi approved in Europe as first treatment for TK2d
- Tozorakimab shows significant benefit in two major COPD trials
